IP Verse

Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation Status - EP2820151

PATENT ANALYSIS

Patent Details

Grant Date
Mar 25, 2020
Company
IRM LLC
Oppositions

BOEHRINGER INGELHEIM RCV GMBH & CO KG / BOEHRINGER INGELHEIM INTERNATIONAL GMBH

More patents of Irm Llc

EP2820151

Want to monitor this patent?

Feel free to send us a message here and we will get back to you